Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study.

Alessandro OttaianoMariachiara SantorsolaFrancesco Perri Vincenza Granata Marco Cascella Francesco SabbatinoGuglielmo Nasti

Published in: Journal of clinical medicine (2023)

we found a significant difference in terms of survival in favor of the TR sequence of treatment. Larger studies are needed to confirm these data and explore specific biomarkers predicting the correct sequence of oral drugs in the treatment of refractory mCRC patients.

Keyphrases

metastatic colorectal cancer
end stage renal disease
ejection fraction
primary care
healthcare
chronic kidney disease
prognostic factors
combination therapy
machine learning
big data
quality improvement
replacement therapy
data analysis